Last reviewed · How we verify
NCT04106323
A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt
trial in Hemophilia in 100 participants. Status unknown.
10 November 2020
Quick facts
| Lead sponsor | Safaa AA Khaled |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 10 May 2020 |
| Primary completion | 10 November 2020 |
| Estimated completion | 20 August 2021 |
Conditions studied
- Hemophilia — all drugs for Hemophilia →
- Von Willebrand Diseases — all drugs for Von Willebrand Diseases →
- Christmas Disease — all drugs for Christmas Disease →
Sponsor
Safaa AA Khaled — full company profile →
Who can join
Adults 18 to 55, any sex, with Hemophilia or Von Willebrand Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hemophilia A and B are bleeding disorders caused by deficiency of factor VIII and IX, respectively. The deficiency of one of these coagulation factors is due to a mutation on the X chromosome. Accordingly replacement of the deficient factor is currently the main treatment for these disorders. The most disappointing complication of replacement therapy in hemophilia is the development of inhibitors. Unlike haemophilia , inhibitor development in patients with V Willebrand's Disease (VWD) is a rare complication of treatment. Studies on inhibitors whether on hemophilia or VWD are limited in our region. This study aims to 1. To estimate the frequency of factor inhibitors in hemophilia and VWD patients in our region. 2. To investigate modifiable risk factors associated with development of inhibitors in both diseases. 3. To correlate the level of inhibitor with the clinical presentation of the patients. 4. To assess influence of factor inhibitors on quality of life in patients who developed factor inhibitors in both diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04106323
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemophilia
Currently open trials in the same condition.
- NCT07579585 — Effects of Photobiomodulation in Hemophilia Patients. · NA · recruiting
- NCT07406139 — PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） · Phase 4 · recruiting
- NCT07285460 — A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Year · Phase 3 · recruiting
- NCT07187661 — Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis · NA · recruiting
- NCT07099313 — Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia · recruiting
Other Safaa AA Khaled trials
Trials by the same sponsor.
- NCT04312607 — Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm · unknown
- NCT03896971 — Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04106323 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Safaa AA Khaled
- Last refreshed: 12 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04106323.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing